The top 3 small bone and joint device companies in the US in 2026 are Stryker, Arthrex and DePuy Synthes, based on market share data from iData Research.
Together, they lead a market built on implants and fixation devices for the shoulder, elbow, hand, wrist, foot and ankle.
iData Research values the U.S. small bone and joint market at nearly $4.6 billion in 2025, growing at 5.5% a year.
Here is how the three compare, and what is changing for the market in 2026.
Find growth niches in minutes, not months.
Explore quick, actionable insights from the select markets.
Table of Contents
➜ Who are the top small bone and joint device companies in 2026
➜ Why Stryker leads the small bone and joint device market
➜ What makes Arthrex a top small bone and joint device company
➜ Why DePuy Synthes ranks among the top small bone and joint device companies
➜ How big is the US small bone and joint device market
➜ What is changing for small bone and joint device companies in 2026
➜ Frequently asked questions about small bone and joint device companies
Key Takeaways
- Stryker, Arthrex and DePuy Synthes are the three leading small bone and joint device companies in the U.S.
- Stryker holds roughly a quarter of the U.S. market and is the only leader with a significant position in all four anatomies.
- Arthrex leads foot and ankle, while DePuy Synthes leads both elbow repair and hand and wrist.
- The U.S. market was worth nearly $4.6 billion in 2025 and is forecast to reach about $6.8 billion by 2032.
Who are the top small bone and joint device companies in 2026
The three leading small bone and joint device companies in the U.S., ranked by 2025 market share, are:
- Stryker
- Arthrex
- DePuy Synthes
Each of these small bone and joint device companies leads a different anatomy, with Stryker first in shoulder reconstruction, Arthrex first in foot and ankle, and DePuy Synthes first in both elbow repair and hand and wrist.
Why Stryker leads the small bone and joint device market
Stryker was the leading small bone and joint device company in the U.S. in 2025, holding roughly a quarter of the total market and a significant position in all four anatomies.
Stryker leads the U.S. primary ankle replacement market, a position it first gained through its 2020 acquisition of Wright Medical.
In June 2025, Stryker received FDA 510(k) clearance for the Incompass Total Ankle System, which combines its Inbone and Infinity ankle technologies into one platform.
In March 2026, Stryker announced that Mako Shoulder is in full market release, combining Tornier Perform Reversed implants, Blueprint planning software and Mako SmartRobotics for reverse shoulder replacement.
iData Research notes that competition is moving toward integrated, procedure-specific platforms rather than implants alone, which suits Stryker’s reach.
What makes Arthrex a top small bone and joint device company
Arthrex ranked second in the U.S. small bone and joint device market in 2025.
It holds the most concentrated position of the three leaders, and it ranks first in the overall foot and ankle device segment.
Most of its small bone and joint revenue comes from foot and ankle devices, where it leads syndesmotic repair, which stabilizes the lower leg bones just above the ankle.
In March 2026, the FDA cleared the Arthrex FibuLock Nail System, which includes the FibuLock PRO fibular nail and a buttress plate designed for use with its TightRope syndesmosis devices.
Unlike Stryker and Zimmer Biomet, Arthrex has invested in planning software rather than robotics, receiving clearance for its Virtual Implant Positioning System for shoulder arthroplasty in October 2024.
Arthrex is also a leader on the sports medicine side of orthopedics, as covered in our ranking of the top orthopedic soft tissue repair companies.
Why DePuy Synthes ranks among the top small bone and joint device companies
DePuy Synthes ranked third among small bone and joint device companies in 2025, driven mainly by internal fixation rather than joint reconstruction.
It leads both the elbow repair and hand and wrist markets, supported by its LCP and VOLT plating platforms.
In June 2025, Johnson & Johnson MedTech launched the VOLT Distal Radius and VOLT Proximal Humerus 3.5 plating systems in the U.S.
In May 2026, DePuy Synthes agreed to acquire selective rights to Gemtrack miniature radiofrequency tracking technology for its joint reconstruction portfolio.
The biggest change is corporate, since Johnson & Johnson announced in October 2025 that it plans to separate DePuy Synthes into a standalone orthopedics company, with a separation now targeted for mid-2027.
How big is the US small bone and joint device market
iData Research valued the U.S. small bone and joint orthopedic device market at nearly $4.6 billion in 2025.
The market is forecast to grow at a 5.5% CAGR to reach approximately $6.8 billion by 2032.
Procedure volume is expected to rise from about 2.6 million in 2025 to about 3.3 million in 2032.
Foot and ankle remains the largest segment, supported by ankle replacement, minimally invasive bunion correction and specialized fixation systems.
Total ankle arthroplasty is now an established surgical option for end-stage ankle arthritis, according to a 2025 systematic review in Diagnostics.
Shoulder reconstruction is expected to grow fastest among the major segments as shoulder arthroplasty adoption continues.
For full segment, procedure and competitor data, see the iData Research U.S. small bone and joint orthopedic device market report.
What is changing for small bone and joint device companies in 2026
Robotics is moving into the shoulder, where Zimmer Biomet’s ROSA Shoulder became the first robotic surgical assistant cleared for shoulder replacement in 2024, and Stryker followed with Mako Shoulder.
For more on how planning tools are changing surgery, see our guide to AI surgical planning in 2026.
In foot and ankle, Zimmer Biomet completed its acquisition of Paragon 28 in April 2025, adding bunion correction, total ankle replacement and Charcot foot reconstruction products.
Hand surgery is shifting toward smaller, image-guided procedures, including Sonex Health’s UltraGuideCTR system for ultrasound-guided carpal tunnel release, which the FDA cleared in 2025.
Together, these moves put more pressure on small bone and joint device companies to compete with full procedure platforms rather than single implants.
Frequently asked questions about small bone and joint device companies
Who is the largest small bone and joint device company in the US?
Stryker is the largest, holding roughly a quarter of the U.S. small bone and joint market in 2025, according to iData Research.
How fast is the US small bone and joint device market growing?
iData Research forecasts a 5.5% CAGR, taking the market from nearly $4.6 billion in 2025 to approximately $6.8 billion by 2032.
Which small bone and joint segment is the largest?
Foot and ankle is the largest segment, while shoulder reconstruction is expected to grow the fastest.
Is DePuy Synthes separating from Johnson & Johnson?
Yes, Johnson & Johnson announced in October 2025 that it plans to separate DePuy Synthes into a standalone orthopedics company, with completion targeted for mid-2027.
Turn market painpoints into opportunities
Explore how procedure trends and competitor positioning create clear openings for industry experts in the market.
